🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Evotec shares surge after technology partnership with Novo Nordisk

Published 09/26/2024, 05:07 AM
© Reuters.
EVTG
-
NVO
-

Investing.com -- Shares of Evotec  (ETR:EVTG)rose on Thursday after the company said it has entered a technology development partnership with Novo Nordisk (NYSE:NVO) in cell therapy.

At 5:08 am (0908 GMT), Evotec was trading 6% higher at €6.250.

Evotec will receive funding from Novo Nordisk for technology development activities in Germany and Italy, along with research and development support, an undisclosed upfront payment, and potential milestone and royalty payments. 

“Together with Novo Nordisk, we are confident to be able to generate novel and robust technologies that will help deliver on the promise of stem cell-based therapies,” said Evotec’s chief scientific officer, Dr Cord Dohrmann.

In return, Novo Nordisk will have the option to secure exclusive rights to utilize the collaboration’s results.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.